File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12876-023-02983-1
- Scopus: eid_2-s2.0-85173770461
- PMID: 37803352
Supplementary
- Citations:
- Appears in Collections:
Article: Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
Title | Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study |
---|---|
Authors | |
Keywords | Anti-Hepatitis B core total antibodies Hepatitis B core antigen Hepatitis B Surface Antigen Hepatitis B Virus Seroclearance |
Issue Date | 6-Oct-2023 |
Publisher | BioMed Central |
Citation | BMC Gastroenterology, 2023, v. 23, n. 1 How to Cite? |
Abstract | Background and Aim: : In chronic hepatitis B infection (CHB), seroclearance of hepatitis B surface antigen (HBsAg) is associated with favourable clinical outcomes compared to those with persistent HBsAg seropositivity, and thus considered as a desired treatment endpoint. This current study explores the possibility of serum antibody to hepatitis B core antigen (anti-HBc) as a potential predictive factor of HBsAg seroclearance. Methods: This is a retrospective study that analyzed the plasma samples of CHB patients using the LUMIPULSE® G1200 analyzer. The longitudinal anti-HBc level between patients who subsequently achieved HBsAg seroclearance (S-losers) and those with persistent HBsAg-positivity (controls) were compared at multiple time points before the event. Results: A total of 240 subjects (120 S-losers and 120 controls; age- and gender-matched) were included (mean age 56.42 ± 10.81, 65% male). Compared to controls, S-losers had significantly lower plasma anti-HBc levels prior to HBsAg seroclearance, with a significant trend of declining plasma anti-HBc 8–5 years prior to HBsAg seroclearance (p < 0.01), while such trend was not observed in controls. ROC curve analysis revealed that plasma anti-HBc at multiple time points before HBsAg seroclearance return AUC greater than 0.7. Plasma anti-HBc level at the cut-off value of 82.50 COI was 68.3% sensitive and 90% specific for HBsAg seroclearance within 1 year. Combining with quantitative HBsAg < 100 IU/mL, anti-HBc < 82.5 COI identified 88.2% patients who would develop HBsAg seroclearance within 1 year. Conclusion: Plasma anti-HBc level began to decline 10 years prior to HBsAg seroclearance and can serve as a potential predictor for subsequent HBsAg seroclearance. |
Persistent Identifier | http://hdl.handle.net/10722/346164 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kan, Karin | - |
dc.contributor.author | Wong, Danny Ka Ho | - |
dc.contributor.author | Hui, Rex Wan Hin | - |
dc.contributor.author | Seto, Wai Kay | - |
dc.contributor.author | Yuen, Man Fung | - |
dc.contributor.author | Mak, Lung Yi | - |
dc.date.accessioned | 2024-09-12T00:30:36Z | - |
dc.date.available | 2024-09-12T00:30:36Z | - |
dc.date.issued | 2023-10-06 | - |
dc.identifier.citation | BMC Gastroenterology, 2023, v. 23, n. 1 | - |
dc.identifier.uri | http://hdl.handle.net/10722/346164 | - |
dc.description.abstract | <p>Background and Aim: : In chronic hepatitis B infection (CHB), seroclearance of hepatitis B surface antigen (HBsAg) is associated with favourable clinical outcomes compared to those with persistent HBsAg seropositivity, and thus considered as a desired treatment endpoint. This current study explores the possibility of serum antibody to hepatitis B core antigen (anti-HBc) as a potential predictive factor of HBsAg seroclearance. Methods: This is a retrospective study that analyzed the plasma samples of CHB patients using the LUMIPULSE® G1200 analyzer. The longitudinal anti-HBc level between patients who subsequently achieved HBsAg seroclearance (S-losers) and those with persistent HBsAg-positivity (controls) were compared at multiple time points before the event. Results: A total of 240 subjects (120 S-losers and 120 controls; age- and gender-matched) were included (mean age 56.42 ± 10.81, 65% male). Compared to controls, S-losers had significantly lower plasma anti-HBc levels prior to HBsAg seroclearance, with a significant trend of declining plasma anti-HBc 8–5 years prior to HBsAg seroclearance (p < 0.01), while such trend was not observed in controls. ROC curve analysis revealed that plasma anti-HBc at multiple time points before HBsAg seroclearance return AUC greater than 0.7. Plasma anti-HBc level at the cut-off value of 82.50 COI was 68.3% sensitive and 90% specific for HBsAg seroclearance within 1 year. Combining with quantitative HBsAg < 100 IU/mL, anti-HBc < 82.5 COI identified 88.2% patients who would develop HBsAg seroclearance within 1 year. Conclusion: Plasma anti-HBc level began to decline 10 years prior to HBsAg seroclearance and can serve as a potential predictor for subsequent HBsAg seroclearance.</p> | - |
dc.language | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.ispartof | BMC Gastroenterology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Anti-Hepatitis B core total antibodies | - |
dc.subject | Hepatitis B core antigen | - |
dc.subject | Hepatitis B Surface Antigen | - |
dc.subject | Hepatitis B Virus | - |
dc.subject | Seroclearance | - |
dc.title | Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12876-023-02983-1 | - |
dc.identifier.pmid | 37803352 | - |
dc.identifier.scopus | eid_2-s2.0-85173770461 | - |
dc.identifier.volume | 23 | - |
dc.identifier.issue | 1 | - |
dc.identifier.eissn | 1471-230X | - |
dc.identifier.issnl | 1471-230X | - |